# JUN 1 3 2014

# 510(k) Summary of Safety and Effectiveness

This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.

# Introduction

According to the requirements of 21 CFR 807.92, the following information provides sufficient detail to understand the basis for a determination of substantial equivalence.

# Submitter Name, Address, and Contact:

Lin-Zhi International, Inc. 670 Almanor Avenue Sunnyvale, CA 94085 Phone: (408) 732-3856 Fax: (408) 732-3849 e-mail: bclin@lin-zhi.com

Contact: Bernice Lin, Ph.D. VP Operations

# Device Name and Classification

Classification Name:

Enzyme Immunoassay, Hydrocodone Class II, DJG (91 Toxicology), 21 CFR 862.3650

Drug Specific Calibrators, Class II, DLJ (91 Toxicology), 21 CFR 862.3200

Drug Specific Controls, Class I, LAS (91 Toxicology), 21 CFR 862.3280

Common Name: Proprietary Name:

Homogeneous Hydrocodone Enzyme Immunoassay LZI Hydrocodone Enzyme Immunoassay, LZI Hydrocodone Drugs of Abuse (DAU) Calibrators 'LZI Hydrocodone Drugs of Abuse (DAU) Controls

# Legally Marketed Predicate Device(s)

The LZI Hydrocodone Enzyme Immunoassay (EIA) is substantially equivalent to the Lin-Zhi International, Inc. Oxycodone Enzyme Immunoassay (k120763) manufactured by Lin-Zhi International, Inc. The LZl Hydrocodone Enzyme Immunoassay is identical or similar to its predicate in terms of intended use, method principle, device components, and clinical performance.

# Device Description

The LZl Hydrocodone assay is a homogeneous enzyme immunoassay with ready-to-use liquid reagents. The assay is based on competition between drug in the sample and drug labeled with the enzyme glucose-6-phosphate dehydrogenase (G6PDH) for a fixed amount of antibody in the reagent. Enzyme activity decreases upon binding to the antibody, and the drug concentration in the sample is measured in terms of enzyme activity. In the absence of drug in the sample, hydrocodone-labeled G6PDH conjugate is bound to antibody, and the enzyme activity is inhibited. On the other hand, when free drug is present in the sample, antibody would bind to free drug; the unbound hydrocodone-labeled G6PDH then exhibits its maximal enzyme activity. Active enzyme converts nicotinamide adenine dinucleotide (NAD) to NADH, resulting in an absorbance change that can be measured spectrophotometrically at $3 4 0 ~ \mathrm { n m }$ .

The LZI Hydrocodone Enzyme Immunoassay is a kit comprised of two reagents, an $\mathsf { R } _ { ! }$ and ${ \sf R } _ { 2 }$ which are bottled separately but sold together within the kit.

The $\mathsf { R } _ { 1 }$ solution contains mouse monoclonal anti-hydrocodone antibody, glucose-6-phosphate (G6P) nicotinamide adenine dinucleotide (NAD), stabilizers, and sodium azide $( 0 . 0 9 \% )$ as a preservative. The ${ \tt R } _ { 2 }$ solution contains glucose-6-phosphate dehydrogenase (G6PDH) labeled with hydrocodone in buffer with sodium azide $( 0 . 0 9 \% )$ as preservative.

The LZI Hydrocodone Enzyme Immunoassay calibrators and controls designated for use at the $1 0 0 ~ \mathrm { { n g / m L } }$ cutoff contain 0, 50, 75, 100, 125, 150, and $3 0 0 ~ \mathrm { n g / m L }$ of hydrocodone in human urine with sodium azide $( 0 . 0 9 \% )$ as preservative. These five calibrators and two controls are sold as individual bottles.

The LZl Hydrocodone Enzyme Immunoassay calibrators and controls designated for use at the $3 0 0 ~ \mathrm { { n g / m L } }$ cutoff contain 0, 150, 225, 300, 375, 500, and $8 0 0 ~ \mathrm { { n g / m L } }$ of hydrocodone in human urine with sodium azide $( 0 . 0 9 \% )$ as preservative. These five calibrators and two controls are sold as individual bottles.

# Intended Use

The LZl Hydrocodone Enzyme Immunoassay is intended for the qualitative and semiquantitative determination of hydrocodone in human urine at the cutoff values of 100 and 300 $\mathfrak { n g / \mathrm { m L } }$ .The assay is designed for prescription use with a number of automated clinical chemistry analyzers.

The semi-quantitative mode is for purposes of (1) enabling laboratories to determine an appropriate dilution of the specimen for confirmation by a confirmatory method such as GCMS and LCMS or (2) permitting laboratories to establish quality control procedures.

The LZl Hydrocodone Drugs of Abuse (DAU) Calibrators are for use as calibrators in the qualitative and semi-quantitative calibration of the LZl Hydrocodone Enzyme Immunoassay at the cutoff values of 100 and $3 0 0 ~ \mathrm { { n g / m L } }$ .

The LZI Hydrocodone Drugs of Abuse (DAU) Controls are for use as assayed quality control materials to monitor the precision of the LZl Hydrocodone Enzyme Immunoassay at the cutoff values of 100 and $3 0 0 ~ \mathrm { { n g / m L } }$ .

The assay provides only a preliminary analytical result. A more specific alternative chemical method must be used in order to obtain a confirmed analytical result. Gas or liquid chromatography/mass spectrometry (GC/MS or LC/MS) is the preferred confirmatory method. Clinical consideration and professional judgment should be exercised with any drug of abuse test result, particularly when the preliminary test result is positive.

# Comparison to Predicate Device

The LZl Hydrocodone Enzyme Immunoassay is substantially equivalent to the Lin-Zhi International, Inc. Oxycodone Enzyme Immunoassay, Calibrators and Controls for Hitachi 717 Systems cleared by the FDA under the premarket notification k120763 for its stated intended use.

The following table compares LZl's Hydrocodone Enzyme Immunoassay with the predicate device.   

<table><tr><td rowspan=1 colspan=1>EY</td><td></td><td></td></tr><tr><td rowspan=1 colspan=1>DeviceCharacteristics</td><td rowspan=1 colspan=1>Subject DeviceLZl Hydrocodone Enzyme Immunoassay,Calibrators and Controls</td><td rowspan=1 colspan=1>Predicate Device (k120763)LZI Oxycodone Enzyme Immunoassay,Calibrators and Controls</td></tr><tr><td rowspan=1 colspan=1>Intended Use</td><td rowspan=1 colspan=1>The LZl Hydrocodone EnzymeImmunoassay, when used in conjunctionwith the AU480 automated clinicalsystem analyzers, is intended for thequalitative and semi-quantitativedetermination of hydrocodone in humanurine at cutoff values of 100 or 300ng/mL. The assay is designed forprofessional use with a number ofautomated clinical chemistry analyzers.This assay provides a rapid screening procedurefor determining the presence of hydrocodone andhydromorphone in urine. The assay provides onlya preliminary analytical result. A more specificalternative chemical method must be used in orderto obtain a confirmed analytical result. Gas orliquid chromatography/mass spectrometry (GC/MSor LC/MS) is the preferred confirmatory method.Clinical consideration and professional judgmentshould be exercised with any drug of abuse testresult, particularly when the preliminary test resultis positive.</td><td rowspan=1 colspan=1>The LZl Oxycodone EnzymeImmunoassay, when used in conjunctionwith Hitachi 717 automated clinicalsystem analyzers, is intended for thequalitative and semi-quantitativedetermination of oxycodone andoxymorphone in human urine at cutoffvalues of 100 or 300 ng/mL. The assay isdesigned for professional use with anumber of automated clinical chemistryanalyzers.This assay provides a rapid screening procedurefor determining the presence of oxycodone andoxymorphone in urine. The assay provides only apreliminary analytical result. A more specificalternative chemical method must be used in orderto obtain a confirmed analytical result. Gas orliquid chromatography/mass spectrometry (GC/MSor LC/MS) is the preferred confirmatory methodClinical consideration and professional judgmentshould be exercised with any drug of abuse testresult, particularly when the preliminary test resultis positive.</td></tr><tr><td rowspan=1 colspan=1>Analyte</td><td rowspan=1 colspan=1>Hydrocodone</td><td rowspan=1 colspan=1>Oxycodone</td></tr><tr><td rowspan=1 colspan=1>Cutoff</td><td rowspan=1 colspan=1>100 or 300 ng/ml</td><td rowspan=1 colspan=1>100 or 300 ng/ml</td></tr><tr><td rowspan=1 colspan=1>Matrix</td><td rowspan=1 colspan=1>Urine</td><td rowspan=1 colspan=1>Urine</td></tr><tr><td rowspan=1 colspan=1>CalibratorsLevel</td><td rowspan=1 colspan=1>100 ng/mL Cutoff: 5 Levels0, 50, 100, 150, and 300 ng/mL300 ng/mL Cutoff: 5 Levels0, 150, 300, 500, and 800 ng/mL</td><td rowspan=1 colspan=1>0, 50, 100, 300, 500, and 800ng/mL</td></tr><tr><td rowspan=1 colspan=1>Controls Level</td><td rowspan=1 colspan=1>100 ng/mL Cutoff: 2 Levels(75 ng/mL, 125 ng/mL)300 ng/mL Cutoff: 2 Levels(225 ng/mL, 375 ng/mL)</td><td rowspan=1 colspan=1>100 ng/mL Cutoff: 2 Levels(75 ng/mL, 125 ng/mL)300 ng/mL Cutoff: 2 Levels(225 ng/mL, 375 ng/mL)</td></tr><tr><td rowspan=1 colspan=1>Storage</td><td rowspan=1 colspan=1>2-8 °C until expiration date</td><td rowspan=1 colspan=1>2-8 °C until expiration date</td></tr></table>

# Performance Characteristics Summary: AU480 Analyzer

Precision: $\mathbf { 1 0 0 \ n g / m L }$ Cutoff

Semi-Quantitative Positive/Negative Results:

The following concentrations were determined with reference curves from 5 calibrators. Typical results were measured as $\mathfrak { n g } / \mathfrak { m L }$ . Positive/Negative results are as follows:

<table><tr><td rowspan=1 colspan=2>100 ng/mL Cutoff Result:</td><td rowspan=1 colspan=2>Within Run (N=22)</td><td rowspan=1 colspan=2>Total Precision (N=88)</td></tr><tr><td rowspan=1 colspan=1>HydrocodoneConcentration</td><td rowspan=1 colspan=1>% of Cutoff</td><td rowspan=1 colspan=1>Number ofDetermination</td><td rowspan=1 colspan=1>ImmunoassayResult</td><td rowspan=1 colspan=1>Number ofDetermination</td><td rowspan=1 colspan=1>ImmunoassayResult</td></tr><tr><td rowspan=1 colspan=1>0 ng/mL</td><td rowspan=1 colspan=1>-100.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>25 ng/mL</td><td rowspan=1 colspan=1>-75.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>50 ng/mL</td><td rowspan=1 colspan=1>-50.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>75 ng/mL</td><td rowspan=1 colspan=1>-25.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>100 ng/mL</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>8 Pos/14 Neg</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>43 Pos/45 Neg</td></tr><tr><td rowspan=1 colspan=1>125 ng/mL</td><td rowspan=1 colspan=1>+25.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>150 ng/mL</td><td rowspan=1 colspan=1>+50.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>175 ng/mL</td><td rowspan=1 colspan=1>+75.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>200 ng/mL</td><td rowspan=1 colspan=1>+100.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr></table>

# Qualitative Positive/Negative Results:

The following concentrations were evaluated. Typical qualitative results were measured as ΔO (mAu). Positive/Negative results are as follows:

<table><tr><td rowspan=1 colspan=2>100 ng/mL Cutoff Result:</td><td rowspan=1 colspan=2>Within Run (N=22)</td><td rowspan=1 colspan=2>Total Precision (N=88)</td></tr><tr><td rowspan=1 colspan=1>HydrocodoneConcentration</td><td rowspan=1 colspan=1>% of Cutoff</td><td rowspan=1 colspan=1>Number ofDetermination</td><td rowspan=1 colspan=1>ImmunoassayResult</td><td rowspan=1 colspan=1>Number ofDetermination</td><td rowspan=1 colspan=1>ImmunoassayResult</td></tr><tr><td rowspan=1 colspan=1>0 ng/mL</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>25 ng/mL</td><td rowspan=1 colspan=1>-75.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>50 ng/mL</td><td rowspan=1 colspan=1>-50.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>75 ng/mL</td><td rowspan=1 colspan=1>-25.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>100 ng/mL</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>7 Pos/ 15 Neg</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>28 Pos/60 Neg</td></tr><tr><td rowspan=1 colspan=1>125 ng/mL</td><td rowspan=1 colspan=1>+25.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>150 ng/mL</td><td rowspan=1 colspan=1>+50.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>175 ng/mL</td><td rowspan=1 colspan=1>+75.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>200 ng/mL</td><td rowspan=1 colspan=1>+100.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr></table>

# Performance Characteristics Summary: (continued) AU480 Analyzer

Precision: ${ \bf 3 0 0 } ~ \bf { n g / m L }$ Cutoff

Semi-Quantitative Positive/Negative Results:

The following concentrations were determined with reference curves from 5 calibrators. Typical results were measured as ng/mL. Positive/Negative results are as follows:

<table><tr><td rowspan=1 colspan=2>300 ng/mL Cutoff Result:</td><td rowspan=1 colspan=2>Within Run (N=22)</td><td rowspan=1 colspan=2>Total Precision (N=88)</td></tr><tr><td rowspan=1 colspan=1>HydrocodoneConcentration</td><td rowspan=1 colspan=1>% of Cutoff</td><td rowspan=1 colspan=1>Number ofDetermination</td><td rowspan=1 colspan=1>ImmunoassayResult</td><td rowspan=1 colspan=1>Number ofDetermination</td><td rowspan=1 colspan=1>ImmunoassayResult</td></tr><tr><td rowspan=1 colspan=1>0 ng/mL</td><td rowspan=1 colspan=1>-100.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>75 ng/mL</td><td rowspan=1 colspan=1>-75.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>150 ng/mL</td><td rowspan=1 colspan=1>-50.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>225 ng/mL</td><td rowspan=1 colspan=1>-25.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>300 ng/mL</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>14 Pos/ 8 Neg</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>47 Pos/ 41 Neg</td></tr><tr><td rowspan=1 colspan=1>375 ng/mL</td><td rowspan=1 colspan=1>+25.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>450 ng/mL</td><td rowspan=1 colspan=1>+50.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>525 ng/mL</td><td rowspan=1 colspan=1>+75.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>600 ng/mL</td><td rowspan=1 colspan=1>+100.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr></table>

# Qualitative Positive/Negative Results:

The following concentrations were evaluated. Typical qualitative results were measured as ΔOL (mAu). Positive/Negative results are as follows:

<table><tr><td rowspan=1 colspan=2>300 ng/mL Cutoff Result:</td><td rowspan=1 colspan=2>Within Run (N=22)</td><td rowspan=1 colspan=2>Total Precision (N=88)</td></tr><tr><td rowspan=1 colspan=1>HydrocodoneConcentration</td><td rowspan=1 colspan=1>% of Cutoff</td><td rowspan=1 colspan=1>Number ofDetermination</td><td rowspan=1 colspan=1>ImmunoassayResult</td><td rowspan=1 colspan=1>Number ofDetermination</td><td rowspan=1 colspan=1>ImmunoassayResult</td></tr><tr><td rowspan=1 colspan=1>0 ng/mL</td><td rowspan=1 colspan=1>-100.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>75 ng/mL</td><td rowspan=1 colspan=1>-75.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>150 ng/mL</td><td rowspan=1 colspan=1>-50.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>225 ng/mL</td><td rowspan=1 colspan=1>-25.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Negative</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Negative</td></tr><tr><td rowspan=1 colspan=1>300 ng/mL</td><td rowspan=1 colspan=1>100.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>11 Pos/11 Neg</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>51 Pos/37 Neg</td></tr><tr><td rowspan=1 colspan=1>375 ng/mL</td><td rowspan=1 colspan=1>+25.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>450 ng/mL</td><td rowspan=1 colspan=1>+50.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>525 ng/mL</td><td rowspan=1 colspan=1>+75.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr><tr><td rowspan=1 colspan=1>600 ng/mL</td><td rowspan=1 colspan=1>+100.0%</td><td rowspan=1 colspan=1>22</td><td rowspan=1 colspan=1>22 Positive</td><td rowspan=1 colspan=1>88</td><td rowspan=1 colspan=1>88 Positive</td></tr></table>

# Performance Characteristics Summary: (continued) AU480 Analyzer

# Linearity: $\mathbf { 1 0 0 \ n g / m L }$ Cutoff

To demonstrate linearity for purposes of sample dilution and quality control (see semiquantitative results section) over the entire assay range, a drug free-urine pool spiked with hydrocodone at $3 0 0 ~ \mathrm { n g / m L }$ was serially diluted. Each sample was run in 10 replicates on the AU480 instrument and the average was used to determine percent recovery compared to the expected target value. When comparing the result (y) and target $\{ \mathbf { x } \}$ value, using the least squares regression technique, the regression equation and correlation are as follow:

$\mathbf { y } = 1 . 0 1 3 9 \mathbf { x } - 1 . 1 7 4$ , $\mathfrak { r } ^ { 2 } = 0 . 9 9 9 5$   

<table><tr><td rowspan=1 colspan=1>Target Concentration(ng/mL)</td><td rowspan=1 colspan=1>Determined(ng/mL)</td><td rowspan=1 colspan=1>% Recovery</td></tr><tr><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>299.0</td><td rowspan=1 colspan=1>99.7%</td></tr><tr><td rowspan=1 colspan=1>250</td><td rowspan=1 colspan=1>· 254.2</td><td rowspan=1 colspan=1>101.7%</td></tr><tr><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>205.6</td><td rowspan=1 colspan=1>102.8%</td></tr><tr><td rowspan=1 colspan=1>175</td><td rowspan=1 colspan=1>177.3</td><td rowspan=1 colspan=1>101.3%</td></tr><tr><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>152.6</td><td rowspan=1 colspan=1>101.7%</td></tr><tr><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>124.9</td><td rowspan=1 colspan=1>99.9%</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>98.2</td><td rowspan=1 colspan=1>98.2%</td></tr><tr><td rowspan=1 colspan=1>75</td><td rowspan=1 colspan=1>73.3</td><td rowspan=1 colspan=1>97.8%</td></tr><tr><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>48.1</td><td rowspan=1 colspan=1>96.1%</td></tr><tr><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>24.1</td><td rowspan=1 colspan=1>96.4%</td></tr><tr><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>73.6%</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>N/A</td></tr></table>

# Linearity: ${ \bf 3 0 0 } ~ \mathrm { n g / m L }$ Cutoff

To demonstrate linearity for purposes of sample dilution and quality control (see semiquantitative results section) over the entire assay range, a drug free-urine pool spiked with hydrocodone at $8 0 0 ~ \mathrm { { n g / m L } }$ was serially diluted. Each sample was run in 10 replicates on the AU480 instrument and the average was used to determine percent recovery compared to the expected target value. When comparing the result (y) and target (x) value, using the least squares regression technique, the regression equation and correlation are as follow:

$\mathbf { y } = 1 . 0 3 1 6 \mathbf { x } + 1 . 1 4 6 1$ , $\mathsf { r } ^ { 2 } = 0 . 9 9 8 8$   

<table><tr><td rowspan=1 colspan=1>Target Concentration(ng/mL)</td><td rowspan=1 colspan=1>Determined(ng/mL)</td><td rowspan=1 colspan=1>% Recovery</td></tr><tr><td rowspan=1 colspan=1>800</td><td rowspan=1 colspan=1>806.3</td><td rowspan=1 colspan=1>100.8%</td></tr><tr><td rowspan=1 colspan=1>700</td><td rowspan=1 colspan=1>736.9</td><td rowspan=1 colspan=1>105.3%</td></tr><tr><td rowspan=1 colspan=1>600</td><td rowspan=1 colspan=1>634.2</td><td rowspan=1 colspan=1>105.7%</td></tr><tr><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>510.1</td><td rowspan=1 colspan=1>102.0%</td></tr><tr><td rowspan=1 colspan=1>425</td><td rowspan=1 colspan=1>445.5</td><td rowspan=1 colspan=1>104.8%</td></tr><tr><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>393.2      -*</td><td rowspan=1 colspan=1>104.9%</td></tr><tr><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>304.4</td><td rowspan=1 colspan=1>101.5%</td></tr><tr><td rowspan=1 colspan=1>225</td><td rowspan=1 colspan=1>230.7</td><td rowspan=1 colspan=1>102.5%</td></tr><tr><td rowspan=1 colspan=1>150</td><td rowspan=1 colspan=1>152.9</td><td rowspan=1 colspan=1>101.9%</td></tr><tr><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>104.0</td><td rowspan=1 colspan=1>104.0%</td></tr><tr><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>12.5</td><td rowspan=1 colspan=1>124.6%</td></tr><tr><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>N/A</td></tr></table>

# Performance Characteristics Summary: (continued) AU480 Analyzer

# Method Comparison - Clinical Samples: $\mathbf { 1 0 0 \ n g / m L }$ Cutoff

Eighty (80) unaltered clinical urine specimens were tested with the LZl Hydrocodone Enzyme Immunoassay and confirmed with GC/MS or LC/MS. Specimens having a hydrocodone and hydromorphone total concentration greater than $1 0 0 ~ \mathrm { { n g / m L } }$ by GC/MS or LC/MS are defined as positive, and specimens with total concentrations below $1 0 0 ~ \mathrm { { n g / m L } }$ by GC/MS or LC/MS are defined as negative in the table below. The correlation results are summarized as follows: (near cutoff samples are defined $a s \pm 5 0 \%$ of the cutoff value). Adjusted Total hydrocodone and hydromorphone GC/MS or LC/MS values corrected for cross-reactivity (Hydrocodone Cross $=$ $100 \%$ , Hydromorphone $\mathrm { C r o s s } = 8 5 \%$ were compared with the EIA result.

Semi-Quantitative & Qualitative Data:

<table><tr><td rowspan=1 colspan=1>100 ng/mLCutoff</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>&lt; 50 % ofthe cutoff</td><td rowspan=1 colspan=1>Near CutoffNeg.</td><td rowspan=1 colspan=1>Near CutoffPos.</td><td rowspan=1 colspan=1>High Pos.</td><td rowspan=1 colspan=1>%Agree-ment</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3*</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>92.5 %</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>3**</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>92.5 %</td></tr></table>

<table><tr><td rowspan=1 colspan=1>100 ng/mLCutoff</td><td rowspan=1 colspan=1>GC/MS orLC/MS</td><td rowspan=1 colspan=1>LZI EIA</td><td rowspan=1 colspan=1>Adjusted TotalHydrocodone+ HydromorphoneGC/MS or LC/MS(ng/mL)</td><td rowspan=1 colspan=1>LZI EIA(ng/mL)</td></tr><tr><td rowspan=1 colspan=1>Sample #37*</td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>85.1</td><td rowspan=1 colspan=1>100.5</td></tr><tr><td rowspan=1 colspan=1>Sample #39*</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>97.0</td><td rowspan=1 colspan=1>105.4</td></tr><tr><td rowspan=1 colspan=1>Sample #40*</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>97.0</td><td rowspan=1 colspan=1>101.6</td></tr><tr><td rowspan=1 colspan=1>Sample #44**</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>128.8</td><td rowspan=1 colspan=1>93.1</td></tr><tr><td rowspan=1 colspan=1>Sample #45**</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>•</td><td rowspan=1 colspan=1>138.5</td><td rowspan=1 colspan=1>93.7</td></tr><tr><td rowspan=1 colspan=1>Sample #46**</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>146.5</td><td rowspan=1 colspan=1>88.1</td></tr></table>

# Performance Characteristics Summary: (continued) AU480 Analyzer

# Method Comparison - Clinical Samples: $\mathbf { 3 0 0 \ n g / m L }$ Cutoff

Eighty (80) unaltered clinical urine specimens were tested with the LZI Hydrocodone Enzyme Immunoassay and confirmed with GC/MS or LC/MS. Specimens having a hydrocodone and hydromorphone total concentration greater than $3 0 0 ~ \mathrm { n g / m L }$ by GC/MS or LC/MS are defined as positive, and specimens with total concentrations below $3 0 0 ~ \mathrm { n g / m L }$ by GC/MS or LC/MS are defined as negative in the table below. The correlation results are summarized as follows: (near cutoff samples are defined ; $1 s \pm 5 0 \%$ of the cutoff value). Adjusted Total hydrocodone and hydromorphone GC/MS or LC/MS values corrected for cross-reactivity (Hydrocodone Cross $=$ EY $100 \%$ , Hydromorphone Cross $= 7 8 \%$ )were compared with the EIA result.

# Semi-Quantitative & Qualitative Data:

<table><tr><td rowspan=1 colspan=1>300 ng/mLCutoff</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>&lt; 50 % of thecutoff</td><td rowspan=1 colspan=1>Near CutoffNeg.</td><td rowspan=1 colspan=1>Near CutoffPos.</td><td rowspan=1 colspan=1>High Pos.</td><td rowspan=1 colspan=1>%Agreement</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>2*</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>32</td><td rowspan=1 colspan=1>95.0 %</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>12</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>2**</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>95.0 %</td></tr></table>

<table><tr><td rowspan=1 colspan=1>300 ng/mLCutoff</td><td rowspan=1 colspan=1>GC/MS orLC/MS</td><td rowspan=1 colspan=1>LZI EIA</td><td rowspan=1 colspan=1>Adjusted TotalHydrocodone+ HydromorphoneGC/MS or LC/MS(ng/mL)</td><td rowspan=1 colspan=1>LZI EIA(ng/mL)</td></tr><tr><td rowspan=1 colspan=1>Sample #36*</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>206.9</td><td rowspan=1 colspan=1>375.5</td></tr><tr><td rowspan=1 colspan=1>Sample #39*</td><td rowspan=1 colspan=1>•</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>246.0</td><td rowspan=1 colspan=1>323.1</td></tr><tr><td rowspan=1 colspan=1>Sample #41**</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>*</td><td rowspan=1 colspan=1>301.0</td><td rowspan=1 colspan=1>252.8</td></tr><tr><td rowspan=1 colspan=1>Sample #43**</td><td rowspan=1 colspan=1>+</td><td rowspan=1 colspan=1>-</td><td rowspan=1 colspan=1>306.2</td><td rowspan=1 colspan=1>254.1</td></tr></table>

# Performance Characteristics Summary: (continued) AU480 Analyzer

# Cross-reactivity: $\mathbf { 1 0 0 \ n g / m L }$ Cutoff

Various potentially interfering substances were tested for interference with the assay. Test compounds were spiked into the drug-free urine pool to various concentrations and evaluated against the cutoff calibrator. The tables below list the concentration of each test compound that gave a response approximately equivalent to that of the cutoff calibrator (as positive) or the maximal concentration of the compound tested that gave a response below the response of the cutoff calibrator (as negative).

# Hydrocodone and Metabolites:

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>ConcentrationEquivalent to CutoffConcentration (ng/mL)</td><td rowspan=1 colspan=1>% Cross-reactivity</td></tr><tr><td rowspan=1 colspan=1>Hydrocodone</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>101.60%</td></tr><tr><td rowspan=1 colspan=1>Hydromorphone</td><td rowspan=1 colspan=1>125</td><td rowspan=1 colspan=1>85.08%</td></tr><tr><td rowspan=1 colspan=1>Hydromorphone Glucuronide</td><td rowspan=1 colspan=1>200</td><td rowspan=1 colspan=1>52.15%</td></tr><tr><td rowspan=1 colspan=1>Dihydrocodeine</td><td rowspan=1 colspan=1>2,000</td><td rowspan=1 colspan=1>4.98%</td></tr><tr><td rowspan=1 colspan=1>Norhydrocodone</td><td rowspan=1 colspan=1>18,000</td><td rowspan=1 colspan=1>0.57%</td></tr></table>

# Structurally Related Compounds:

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>ConcentrationEquivalent to CutoffConcentration (ng/mL)</td><td rowspan=1 colspan=1>% Cross-reactivity</td></tr><tr><td rowspan=1 colspan=1>6-mono acetylmorphine</td><td rowspan=1 colspan=1>6,500</td><td rowspan=1 colspan=1>1.6%</td></tr><tr><td rowspan=1 colspan=1>Codeine</td><td rowspan=1 colspan=1>3,000</td><td rowspan=1 colspan=1>3.5%</td></tr><tr><td rowspan=1 colspan=1>Codeine-6-Glucuronide</td><td rowspan=1 colspan=1>15,000</td><td rowspan=1 colspan=1>0.6%</td></tr><tr><td rowspan=1 colspan=1>Dextromethorphan</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Levorphanol</td><td rowspan=1 colspan=1>20,000</td><td rowspan=1 colspan=1>0.5%</td></tr><tr><td rowspan=1 colspan=1>Morphine</td><td rowspan=1 colspan=1>5,000</td><td rowspan=1 colspan=1>2.0%</td></tr><tr><td rowspan=1 colspan=1>Morphine 3-Glucuronide</td><td rowspan=1 colspan=1>13,000</td><td rowspan=1 colspan=1>0.8%</td></tr><tr><td rowspan=1 colspan=1>Morphine 6-Glucuronide</td><td rowspan=1 colspan=1>50,000</td><td rowspan=1 colspan=1>0.2%</td></tr><tr><td rowspan=1 colspan=1>Nalbuphine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Naloxone</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Naltrexone</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Norcodeine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Noroxycodone</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Noroxymorphone</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>0.0%</td></tr><tr><td rowspan=1 colspan=1>Oxycodone</td><td rowspan=1 colspan=1>5,000</td><td rowspan=1 colspan=1>2.1%</td></tr><tr><td rowspan=1 colspan=1>Oxymorphone</td><td rowspan=1 colspan=1>7,500</td><td rowspan=1 colspan=1>1.3%</td></tr><tr><td rowspan=1 colspan=1>Thebaine</td><td rowspan=1 colspan=1>12,000</td><td rowspan=1 colspan=1>0.8%</td></tr></table>

No significant cross-reactivity with structurally un-related compounds was observed.

The labeling contains the list of structurally unrelated compounds that were tested.

# Performance Characteristics Summary: (continued) AU480 Analyzer

# Cross-reactivity: $\mathbf { 3 0 0 } ~ \mathbf { n g / m L }$ Cutoff

Various potentially interfering substances were tested for interference with the assay. Test compounds were spiked into the drug-free urine pool to various concentrations and evaluated against the cutoff calibrator. The tables below list the concentration of each test compound that gave a response approximately equivalent to that of the cutoff calibrator (as positive) or the maximal concentration of the compound tested that gave a response below the response of the cutoff calibrator (as negative).

# Hydrocodone and Metabolites:

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>ConcentrationEquivalent to CutoffConcentration (ng/mL)</td><td rowspan=1 colspan=1>% Cross-reactivity</td></tr><tr><td rowspan=1 colspan=1>Hydrocodone</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>99.70%</td></tr><tr><td rowspan=1 colspan=1>Hydromorphone</td><td rowspan=1 colspan=1>375</td><td rowspan=1 colspan=1>78.13%</td></tr><tr><td rowspan=1 colspan=1>Hydromorphone Glucuronide</td><td rowspan=1 colspan=1>625</td><td rowspan=1 colspan=1>49.15%</td></tr><tr><td rowspan=1 colspan=1>Dihydrocodeine</td><td rowspan=1 colspan=1>8,750</td><td rowspan=1 colspan=1>3.32%</td></tr><tr><td rowspan=1 colspan=1>Norhydrocodone</td><td rowspan=1 colspan=1>30,000</td><td rowspan=1 colspan=1>0.51%</td></tr></table>

# Structurally Related Compounds:

<table><tr><td rowspan=1 colspan=1>Compound</td><td rowspan=1 colspan=1>ConcentrationEquivalent to CutoffConcentration (ng/mL)</td><td rowspan=1 colspan=1>% Cross-reactivity</td></tr><tr><td rowspan=1 colspan=1>6-monoacetylmorphine</td><td rowspan=1 colspan=1>30,000</td><td rowspan=1 colspan=1>1.00%</td></tr><tr><td rowspan=1 colspan=1>Codeine</td><td rowspan=1 colspan=1>13,400</td><td rowspan=1 colspan=1>2.16%</td></tr><tr><td rowspan=1 colspan=1>Codeine-6-Glucuronide</td><td rowspan=1 colspan=1>80,000</td><td rowspan=1 colspan=1>0.37%</td></tr><tr><td rowspan=1 colspan=1>Dextromethorphan</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>0.00%</td></tr><tr><td rowspan=1 colspan=1>Levorphanol</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>0.32%</td></tr><tr><td rowspan=1 colspan=1>Morphine</td><td rowspan=1 colspan=1>22,000</td><td rowspan=1 colspan=1>1.30%</td></tr><tr><td rowspan=1 colspan=1>Morphine 3-Glucuronide</td><td rowspan=1 colspan=1>37,000</td><td rowspan=1 colspan=1>0.73%</td></tr><tr><td rowspan=1 colspan=1>Morphine 6-Glucuronide</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>0.17%</td></tr><tr><td rowspan=1 colspan=1>Nalbuphine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>0.01%</td></tr><tr><td rowspan=1 colspan=1>Naloxone</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>0.03%</td></tr><tr><td rowspan=1 colspan=1>Naltrexone</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>0.01%</td></tr><tr><td rowspan=1 colspan=1>Norbuprenorphine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>0.01%</td></tr><tr><td rowspan=1 colspan=1>Norcodeine</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>0.02%</td></tr><tr><td rowspan=1 colspan=1>Noroxycodone</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>0.02%</td></tr><tr><td rowspan=1 colspan=1>Noroxymorphone</td><td rowspan=1 colspan=1>100,000</td><td rowspan=1 colspan=1>0.27%</td></tr><tr><td rowspan=1 colspan=1>Oxycodone</td><td rowspan=1 colspan=1>20,000</td><td rowspan=1 colspan=1>0.08%</td></tr><tr><td rowspan=1 colspan=1>Oxymorphone</td><td rowspan=1 colspan=1>35,000</td><td rowspan=1 colspan=1>0.90%</td></tr><tr><td rowspan=1 colspan=1>Thebaine</td><td rowspan=1 colspan=1>25,000</td><td rowspan=1 colspan=1>0.75%</td></tr></table>

No significant cross-reactivity with structurally un-related compounds was observed.

The labeling contains the list of structurally unrelated compounds that were tested.

# Performance Characteristics Summary: (continued) AU480 Analyzer

# Interference: 100 ng/mL Cutoff

# Endogenous Compound Interference Study: $\mathbf { 1 0 0 \ n g / m L }$ Cutoff

Various endogenous compounds were tested for interference with the assay. Test compounds were spiked into a pool of drug-free processed urine to the spiked concentrations listed in the table below. Each of these samples were split into three portions each and either left unspiked or further spiked to either 75 or $1 2 5 ~ \mathrm { n g / m L }$ of hydrocodone (the negative and positive control concentrations, respectively). These samples were then evaluated in both semi-quantitative or qualitative mode. The tables below list the positive or negative result of each test sample relative to the cutoff calibrator (positive above the cutoff calibrator and negative below the cutoff calibrator).

<table><tr><td rowspan=2 colspan=1>Endogenous Substance</td><td rowspan=2 colspan=1>Spiked Concentration(mg/dL)</td><td rowspan=1 colspan=3>Spiked Hydrocodone Concentration</td></tr><tr><td rowspan=1 colspan=1>0ng/mL</td><td rowspan=1 colspan=1>75 Controlng/mL</td><td rowspan=1 colspan=1>125 Controlng/mL</td></tr><tr><td rowspan=1 colspan=1>Acetone</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Creatinine</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Ethanol</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Galactose</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>γ-Globulin</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Glucose</td><td rowspan=1 colspan=1>3000</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>HSA</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Oxalic Acid</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Riboflavin</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Urea</td><td rowspan=1 colspan=1>6000</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Sodium Chloride</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr></table>

# Performance Characteristics Summary: (continued) AU480 Analyzer

# pH Interference Study: $\mathbf { 1 0 0 \ n g / m L }$ Cutoff

Pooled drug-free processed urine samples were adjusted to the target pH values (3  11) using 1N HCl or 1N NaOH. These samples were split into three portions each and either left unspiked or further spiked to either 75 or $1 2 5 ~ \mathrm { { n g / m L } }$ of hydrocodone (the negative and positive control concentrations, respectively). These samples were then evaluated in both semi-quantitative or qualitative mode.The tables below list the positive or negative result of each test sample relative to the cutoff calibrator (positive above the cutoff calibrator and negative below the cutoff calibrator).

<table><tr><td rowspan=2 colspan=1>pH</td><td rowspan=1 colspan=3>Spiked Hydrocodone Concentration</td></tr><tr><td rowspan=1 colspan=1>0 ng/mL</td><td rowspan=1 colspan=1>75 Controlng/mL</td><td rowspan=1 colspan=1>125 Controlng/mL</td></tr><tr><td rowspan=1 colspan=1>pH 3</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>pH 4</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>pH 5</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>pH6</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>pH 7</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>pH8</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>pH9</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>pH 10</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>pH 11</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr></table>

# Specific Gravity: $\mathbf { 1 0 0 \ n g / m L }$ Cutoff

Ten drug-free urine samples with specific gravity ranging in value from l.000 to 1.030 were split into three portions each and either left un-spiked or further spiked to a final hydrocodone concentration of either 75 or $1 2 5 \mathrm { \ n g / m L }$ (the negative and positive control concentrations, respectively). These samples were then evaluated in semi-quantitative and qualitative modes. The tables below list the positive or negative result of each test sample relative to the cutoff calibrator (positive above the cutoff calibrator and negative below the cutoff calibrator).

<table><tr><td rowspan=2 colspan=1>SpecificGravity</td><td rowspan=1 colspan=3>Spiked Hydrocodone Concentration</td></tr><tr><td rowspan=1 colspan=1>0 ng/mL</td><td rowspan=1 colspan=1>75 Controlng/mL</td><td rowspan=1 colspan=1>125 Controlng/mL</td></tr><tr><td rowspan=1 colspan=1>1.000</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>1.005</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>1.007</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>1.010</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>1.015</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>1.017</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>1.020</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>1.025</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>1.027</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>1.030</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr></table>

No significant undesired endogenous substance interference, $\mathsf { p H }$ interference, or specific gravity interference was observed at the $\mathfrak { i } 0 0 \ : \mathrm { n g / m L }$ Cutoff.

# Performance Characteristics Summary: (continued) AU480 Analyzer

Interference: ${ \bf 3 0 0 } ~ \bf { n g / m L }$ Cutoff

# Endogenous Compound Interference Study: $\bf { 3 0 0 } \ n g / \dot { m } L$ Cutoff

Various endogenous compounds were tested for interference with the assay. Test compounds were spiked into a pool of drug-free processed urine to the spiked concentrations listed in the table below. Each of these samples were split into three portions each and either left unspiked or further spiked to either 225 or $3 7 5 n g / \mathrm { m L }$ of hydrocodone (the negative and positive control concentrations, respectively). These samples were then evaluated in both semi-quantitative or qualitative mode. The tables below list the positive or negative result of each test sample relative to the cutoff calibrator (positive above the cutoff calibrator and negative below the cutoff calibrator).

<table><tr><td rowspan=2 colspan=1>Endogenous Substance</td><td rowspan=2 colspan=1>Spiked Concentration(mg/dL)</td><td rowspan=1 colspan=3>Spiked Hydrocodone Concentration</td></tr><tr><td rowspan=1 colspan=1>0ng/mL</td><td rowspan=1 colspan=1>225 Controlng/mL</td><td rowspan=1 colspan=1>375 Controlng/mL</td></tr><tr><td rowspan=1 colspan=1>Acetone</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Creatinine</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Ethanol</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Galactose</td><td rowspan=1 colspan=1>10</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>γ-Globulin</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Glucose</td><td rowspan=1 colspan=1>3000</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>300</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>HSA</td><td rowspan=1 colspan=1>500</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Oxalic Acid</td><td rowspan=1 colspan=1>100</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Riboflavin</td><td rowspan=1 colspan=1>0.3</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Urea</td><td rowspan=1 colspan=1>6000</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>Sodium Chloride</td><td rowspan=1 colspan=1>1000</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr></table>

# Performance Characteristics Summary: (continued) AU480 Analyzer

pH Interference Study: ${ \bf 3 0 0 } ~ \bf { n g / m L }$ Cutoff

Pooled drug-free processed urine samples were adjusted to the target pH values (3  11) using 1N HCl or IN NaOH. These samples were split into three portions each and either left unspiked or further spiked to either 225 or $3 7 5 ~ \mathrm { n g / m L }$ of hydrocodone (the negative and positive control. concentrations, respectively). These samples were then evaluated in both semi-quantitative or qualitative mode. The tables below list the positive or negative result of each test sample relative to the cutoff calibrator (positive above the cutoff calibrator and negative below the cutoff calibrator).

<table><tr><td rowspan=2 colspan=1>pH</td><td rowspan=1 colspan=3>Spiked Hydrocodone Concentration</td></tr><tr><td rowspan=1 colspan=1>0 ng/mL</td><td rowspan=1 colspan=1>225 Controlng/mL</td><td rowspan=1 colspan=1>375 Controlng/mL</td></tr><tr><td rowspan=1 colspan=1>pH 3</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>$p{H  $</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>pH5</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>pH 6</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>pH 7</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>pH 8</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>pH 9</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>pH 10</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>pH 11</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr></table>

# Specific Gravity: ${ \bf 3 0 0 } ~ \bf { n g / m L }$ Cutoff

Ten drug-free urine samples with specific gravity ranging in value from 1.000 to 1.030 were split into three portions each and either left un-spiked or further spiked to a final hydrocodone concentration of either 225 or $3 7 5 \mathrm { \ n g / m L }$ (the negative and positive control concentrations, respectively). These samples were then evaluated in semi-quantitative and qualitative modes. The tables below list the positive or negative result of each test sample relative to the cutoff calibrator (positive above the cutoff calibrator and negative below the cutoff calibrator).

<table><tr><td rowspan=2 colspan=1>SpecificGravity</td><td rowspan=1 colspan=3>Spiked Hydrocodone Concentration</td></tr><tr><td rowspan=1 colspan=1>0 ng/mL</td><td rowspan=1 colspan=1>225 Controlng/mL</td><td rowspan=1 colspan=1>375 Controlng/mL</td></tr><tr><td rowspan=1 colspan=1>1.000</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>1.005</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>1.007</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>1.010</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>}   Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>1.015</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>1.017</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>1.020</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>1.025</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>1.027</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr><tr><td rowspan=1 colspan=1>1.030</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Neg</td><td rowspan=1 colspan=1>Pos</td></tr></table>

No significant undesired endogenous substance interference, $\mathsf { p H }$ interference, or specific gravity interference was observed at the $3 0 0 ~ \mathrm { { n g / m L } }$ Cutoff.

# Performance Characteristics Summary: (continued) AU480 Analyzer

# Stability for Calibrators and Controls: $\mathbf { 1 0 0 \ n g / m L }$ Cutoff

Current open-vial calibrator/control stability studies at Cold Temperature $( 2 { - } 8 ^ { \circ } \mathrm { C } )$ , Room temperature $( \sim 2 5 ~ ^ { \circ } \mathrm { C } )$ , and Accelerated Temperature $( 3 0 ^ { \circ } \mathrm { C } )$ are on-going and have been carried out up to Day 92 at this time. Results from open-vial studies indicate that degradation is minimal at all three conditions up to Day 92 and based on the Arrhenius Equation, suggest an open-vial stability of up to 18 months.

Real-time data orclosed-vial calibrator/control stability udies at Cold Tempeatu $( 2 { \cdot } 8 ^ { \circ } \mathrm { C } )$ are on-going have been carried out up to Day 114. Results from closed-vial studies indicate that degradation is minimal up to Day I 14 as compared to Day 1.

# Stability for Calibrators and Controls: $\mathbf { 3 0 0 } ~ \mathbf { n g / m L }$ Cutoff

Current open-vial calibrator/control stability studies at Cold Temperature $( 2 { - } 8 ^ { \circ } \mathrm { C } )$ , Room temperature $( { \sim } 2 5 ^ { \circ } \mathrm { C } )$ , and Accelerated Temperature $( 3 0 ^ { \circ } \mathrm { C } )$ are on-going and have been carried out up to Day 225 at this time. Results from open-vial studies indicate that degradation is minimal at all three conditions up to Day 225 and based on the Arrhenius Equation, suggest an open-vial stability of up to 18 months.

Real-time data for closed-vial calibrator/control stability studies at Cold Temperature $( 2 { - } 8 ^ { \circ } \mathrm { C } )$ are on-going have been carried out up to Day 114. Results from closed-vial studies indicate that degradation is minimal up to Day I 14 as compared to Day I.

# Summary:

The information provided in this pre-market notification demonstrates that the LZI Hydrocodone Enzyme Immunoassay is substantially equivalent to the legally marketed predicate device for its general intended use. Substantial equivalence was demonstrated through comparison of intended use and physical properties to the commercially available predicate device as confirmed by chromatography/mass spectrometry (GC/MS or LC/MS), an independent analytical method. The information supplied in this pre-market notification provides reasonable assurance that the LZl Hydrocodone Enzyme Immunoassay is safe and effective for its stated intended use.

Dear Dr. Bernice Lin:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices hat have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with allthe Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Parts 801 and 809); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the

electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000- 1050.

If you desire specific advice for your device on our labeling regulations (21 CFR Parts 801 and 809), please contact the Division of Industry and Consumer Education at its tol-ree number (800638-2041r(301)796-7100orat itsInternetaddress   
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

# Courtney H Lias -S

Courtney H. Lias, Ph.D.   
Director   
Division of Chemistry and Toxicology Devices Office of In Vitro Diagnostics   
and Radiological Health   
Center for Devices and Radiological Health

LZI Hydrocodone Enzyme Immunoassay and LZI Hydrocodone Calibrators and Controls

Indications for Use (Describe)

The LZI Hydrocodone Enzyme Immunoassay is intended for the qualitative and semi-quantitative determination hyon hi he utal 0nd 0 / whcalratagi ocee is designed for prescription use with a number of automated clinical chemistry analyzers.

Th quivod u anadrilu e ain aoy e  CM n LMr p quality control procedures.

The LZI Hydrocodone Drug of Abuse (DAU) Calibrators are oruse as calibrators in he qualitative andsemiquantitative calibration of the LZ Hydrocodone Enzyme Immunoassay at the cutof value of 100 and 300 ng/mL. The LZ Hydroce Drug Abuse DAU) Controls a r use  assaye quali contolmaterials tmorhe precision of the LZI Hydrocodone Enzyme Immunoassay at the cutoff value of 100 and 300 ng/mL.

The ie alylu eis btacmnalytical eua quirtah/mass ey C/MSr C/S proyt.Cl ei oesial j oul  e abuse test result, particularly when the preliminary test result is positive

This section applies only to requirements of the Paperwork Reduction Act of 1995.

# \*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The buren  ohi colection noation s tate vergehours peonclud time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff@fda.hs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."